2026-03-26 20:42:32
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results with Revenue Decline
Expected Stock impact: Slightly Negative
CV Sciences, Inc. (OTCQB:CVSI) has released its financial results for the fiscal year and quarter ending December 31, 2025. The company reported a revenue of $13.8 million for the fiscal year, down from $15.7 million in 2024, indicating a decline of 12.2%. For the fourth quarter of 2025, revenue was $3.3 million, consistent with the third quarter but lower than the $3.9 million reported in the same quarter of the previous year. The decline in revenue is attributed to lower sales volume due to temporary out-of-stock issues for key products and restrictive regulations at the federal and state levels. Despite the revenue drop, the company recognized a gross margin of 49.0% for the fiscal year, an improvement from 45.6% in 2024. The fourth quarter gross margin was reported at 50.5%, up from 43.2% in the same quarter last year. Operating expenses were reduced by 17.2% to $7.7 million for the fiscal year, contributing to a significant decrease in operating loss to $0.5 million from $2.2 million in 2024. The adjusted EBITDA loss improved to $0.3 million from $0.8 million in the previous year, with a positive adjusted EBITDA of $0.1 million for the fourth quarter, a notable turnaround from losses in the previous quarters. The company also highlighted the launch of new products and a successful debt restructuring aimed at strengthening its financial position. CEO Joseph Dowling stated that the company is focused on improving margins, reducing costs, and moving towards sustainable profitability while exploring growth opportunities through strategic acquisitions.
